March 2026 FDA Recall Icosapent Ethyl by Zydus Pharmaceuticals (usa) Inc (D-0400-2026 - Failed Tablet/Capsule specifications)

This Class II drug recall was voluntarily initiated by Zydus Pharmaceuticals (usa) Inc on March 9, 2026 for the product Icosapent Ethyl. The FDA reported the reason for recall as failed tablet/capsule specifications. The product was distributed Nationwide and the recall is currently ongoing.

Recall Number: D-0400-2026

Reason for Recall
Failed Tablet/Capsule specifications: Red dots inside capsule and melted capsule caused by oxidized Icosapent ethyl, the active ingredient.
Initiated
03-09-2026
Reported
03-18-2026
Quantity
60,541 bottles

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Zydus Pharmaceuticals (USA) Inc
Nationwide in the USA
Icosapent Ethyl Capsules, 1 gram, 120 Capsules per bottle, Rx only, Manufactured by: Softgel Healthcare Pvt. Ltd., India; Distributed by: Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534. NDC: 70710-1592-7

Batch or Lot Expiration Information

Lot# : S2520249, S2520250, S2520267, Exp. Date 2027/Jan; S2520303, S2520305, S2520332, Exp. Date 2027/Feb; S2540208, S2540209, Exp. Date 2027/Apr

Affected Packages Involved in this Recall